Research Overview

GeroNova Research is setting the industry standards for research, analysis and lipoic acid products.

GeroNova Publications

Pharmaceutical Composition Comprising an Enantiomer of Lipoamide and Derivatives Thereof and Methods of Use.

US Patent: 9,351, 956 B1 (May 31, 2016). Link to pdf.

R-(+)-Lipoamide has been shown to be more potent than R-(+)-lipoic acid in several model hepatic systems. In vivo plasma analysis of p.o. and i.v. administered lipoamide reveals only lipoic acid in circulation even at the first sampling time point thus highlighting the limitations of extrapolating in vitro studies to living organisms. Despite this apparent limitation, lipoamide has been detected at therapeutically useful levels in liver for an hour before the amide is hydrolyzed back to lipoic acid and numerous metabolites. Our signal transduction studies have demonstrated this time course is sufficient to activate cellular signaling pathways responsible for upregulation of early response genes associated with hepatic protection, detoxification and liver regeneration. Currently the primary treatment protocol for liver failure is transplant. Therefore further research is indicated to test the effects of lipoamide and other amide derivatives for the ability to regenerate damaged hepatic tissues. If you are interested in developing lipoamide and derivatives as a pharmaceutical agent or a dietary supplement, please contact us.

Interaction of α-Lipoic Acid with the Human Na+/Multivitamin Transporter (hSMVT).

J Biol Chem. 2015 Jun 26;290(26):16372-82. doi: 10.1074/jbc.M114.622555. Epub 2015 May 13.
Zehnpfennig B1, Wiriyasermkul P2, Carlson DA3, Quick M4.

Read the abstract on pubmed

Author Affiliations:
  1. From the Center for Molecular Recognition and
  2. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York 10032.
  3. GeroNova Research, Inc., Richmond, California 94806, and david@geronova.com.
  4. From the Center for Molecular Recognition and Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York 10032, Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032 mq2102@cumc.columbia.edu.

Contrasting effects of lipoic acid and lipoamide on mitochondrial biogenesis and mitochondrial function: implications for diabetes prevention and aging: a hypothesis paper.

Journal of Bioscience and Medicine 2012, 1:5  Shen W.(1) Carlson DA.(2) Cadenas E.(3) Packer L.(3,4) and Liu J.(3,4)
Author Affiliations:
  1. State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Vascular Biology and Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
  2. GeroNova Research, Inc., Richmond, CA 94804, USA.
  3. Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
  4. Center for Mitochondrial Biology and Medicine, School of Life Science & Technology and Frontier Institute of Life Science, FIST, Xi’an Jiaotong University, Xi’an 710049, China.

Evaluation of the Role of Chirality and Amide Substitution in Redox Modulation of Signal Transduction by Lipoic Acid and Derivatives.

Poster Presentation, Oxygen Club of California, Alba, Italy June 20-23, 2012. Carlson DA.(1) He DY.(1) Kalashnikova E.(1) Gendelman R.(1, 2) Fischer SJ.(1), Packer L.(3)

View Poster

Author Affiliations:
  1. GeroNova Research Inc, 2600 Hilltop Drive, Building B, Suite C120 Richmond CA. 94806
  2. University of California San Francisco Cancer Center, San Francisco, CA 94115
  3. Pharmacy and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089

Therapeutic Potential of Lipoamide and Enhanced Mitochondrial Biogenesis for Treatment of Insulin Resistance

Shen W, Carlson DA, Packer L, Cadenas E, Liu J. Chapter 5 in Mitochondrial Signaling in Health and  Disease (93-111) Eds. Orrenius S, Cadenas E and Packer L. CRC Press, Taylor & Francis Group, Boca Raton, London, New York (2012)

Read the article

The Thioctic Acid/Lipoic Acid Legacy Archive Project 2010

David A. Carlson & Sarah J. Fischer

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease

Maczurek A (b,c), Hager K (a), Kenlies M (a), Sharman M (d), Martins R (a), Engel J (e), Carlson DA (f), Münch G (b,c). Advanced Drug Delivery Reviews (2008)

Read the abstract on the Pub Med website

Author Affiliations

a. Klinik für Medizinische Rehabilitation und Geriatrie der Henriettenstiftung,
Hannover, Germany
b. Dept. of Pharmacology, School of Medicine, University of Western Sydney,
Australia
c. Dept. of Biochemistry and Molecular Biology, James Cook University,
Townsville
d. Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan
University, Australia
e. Zentaris GmbH, Frankfurt am Main, Germany
f. GeroNova Research, Inc., Richmond, CA, USA

An Evaluation of the Stability and Pharmacokinetics of R-lipoic Acid and R-Dihydrolipoic Acid Dosage Forms in Plasma from Healthy Human Subjects

Carlson DA, Young KL, Fischer SJ, Ulrich H. Chapter 10 in: Packer L, Patel M, eds.Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects. London, England: Taylor & Francis Publishers; 2008:235-270.

The Plasma Pharmacokinetics of R-(+)-Lipoic Acid Administered as Sodium R-(+)-Lipoate to Healthy Human Subjects.

Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L. Altern Med Rev 2007;12(4) 343-351

A comparison of the pharmacokinetic profiles of lipoate enantiomers with the racemic mixture in healthy human subjects indicates possible stereoselective gut transport.

Carlson DA, Smith AR, Fischer SJ, Young KL.

Further characterization of the lipoic acid enantiomers provide new research opportunities. Stereochemistry, Pharmacokinetics & Metabolism:Toward a Comprehensive Mechanism of Action

Oxygen Club of California PowerPoint presentation by David A.Carlson, March,15, 2008.

Lipoic acid in Alzheimer’s disease – From basic therapeutic concepts to clinical trials

Marlies Kenklies, Klaus Hager, Gerald Münch, Shanmugam Kirubakaran, Annette Maczurek, Grant Stuchbury, David Carlson

The case against controlled release lipoic acid: A pharmacokinetic-mechanistic argument (part 1)

A chronological listing of Lipoic Acid conferences

Contact us if you know of other Lipoic Acid conferences not listed